IRadimed Corporation
NASDAQ:IRMD
54.65 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 65.562 | 53.303 | 41.815 | 31.717 | 38.517 | 30.439 | 23.082 | 32.497 | 31.594 | 15.653 | 11.34 | 7.685 |
| Cost of Revenue
| 15.404 | 12.021 | 9.765 | 8.143 | 8.816 | 7.212 | 5.57 | 6.155 | 5.84 | 3.404 | 2.853 | 2.126 |
| Gross Profit
| 50.158 | 41.282 | 32.05 | 23.574 | 29.701 | 23.227 | 17.512 | 26.342 | 25.753 | 12.249 | 8.487 | 5.559 |
| Gross Profit Ratio
| 0.765 | 0.774 | 0.766 | 0.743 | 0.771 | 0.763 | 0.759 | 0.811 | 0.815 | 0.783 | 0.748 | 0.723 |
| Reseach & Development Expenses
| 2.859 | 2.278 | 1.905 | 1.903 | 1.433 | 1.517 | 1.723 | 1.348 | 1.764 | 1.069 | 1.01 | 0.654 |
| General & Administrative Expenses
| 15.122 | 10.697 | 9.771 | 12.269 | 10.451 | 8.711 | 9.001 | 8.796 | 7.77 | 4.817 | 2.392 | 1.55 |
| Selling & Marketing Expenses
| 12.142 | 12.68 | 10.556 | 10.159 | 9.17 | 6.996 | 5.503 | 5.278 | 4.706 | 3.297 | 2.297 | 1.93 |
| SG&A
| 27.264 | 23.377 | 20.327 | 22.428 | 19.621 | 15.706 | 14.504 | 14.074 | 12.476 | 8.114 | 4.69 | 3.48 |
| Other Expenses
| 0 | 0.553 | 0.019 | 0.139 | 0.396 | 0.194 | 0.111 | 0.033 | 0.121 | -0.049 | -0.003 | 0.007 |
| Operating Expenses
| 30.123 | 25.655 | 22.232 | 24.331 | 21.054 | 17.224 | 16.227 | 15.422 | 14.24 | 9.183 | 5.699 | 4.134 |
| Operating Income
| 20.035 | 15.628 | 9.818 | -0.756 | 8.647 | 6.004 | 1.285 | 10.92 | 11.513 | 3.066 | 2.787 | 1.425 |
| Operating Income Ratio
| 0.306 | 0.293 | 0.235 | -0.024 | 0.225 | 0.197 | 0.056 | 0.336 | 0.364 | 0.196 | 0.246 | 0.185 |
| Total Other Income Expenses Net
| 1.703 | 0.553 | 0.019 | 0.139 | 0.396 | 0.194 | 0.111 | 0.033 | 0.121 | -0.049 | -0.003 | 0.007 |
| Income Before Tax
| 21.738 | 16.181 | 9.836 | -0.617 | 9.043 | 6.197 | 1.396 | 10.953 | 11.635 | 3.017 | 2.784 | 1.432 |
| Income Before Tax Ratio
| 0.332 | 0.304 | 0.235 | -0.019 | 0.235 | 0.204 | 0.06 | 0.337 | 0.368 | 0.193 | 0.245 | 0.186 |
| Income Tax Expense
| 4.545 | 3.353 | 0.511 | -1.986 | -0.588 | -0.106 | 0.897 | 3.738 | 4.105 | 0.967 | 0.847 | 0.466 |
| Net Income
| 17.193 | 12.828 | 9.325 | 1.369 | 9.631 | 6.303 | 0.5 | 7.215 | 7.53 | 2.05 | 1.937 | 0.966 |
| Net Income Ratio
| 0.262 | 0.241 | 0.223 | 0.043 | 0.25 | 0.207 | 0.022 | 0.222 | 0.238 | 0.131 | 0.171 | 0.126 |
| EPS
| 1.36 | 1.02 | 0.76 | 0.11 | 0.85 | 0.52 | 0.05 | 0.67 | 0.68 | 0.23 | 0.19 | 0.093 |
| EPS Diluted
| 1.35 | 1.02 | 0.74 | 0.11 | 0.78 | 0.52 | 0.04 | 0.6 | 0.6 | 0.2 | 0.19 | 0.093 |
| EBITDA
| 20.801 | 16.298 | 11.225 | 0.583 | 9.89 | 7.109 | 2.594 | 11.168 | 11.513 | 3.215 | 2.926 | 1.531 |
| EBITDA Ratio
| 0.317 | 0.293 | 0.268 | 0.018 | 0.257 | 0.234 | 0.112 | 0.344 | 0.372 | 0.205 | 0.258 | 0.199 |